Given the proportion of all breast/ovarian cancer families in our population attributable to recurring mutations, a cost-effective stepwise molecular screening strategy of BRCA1 and BRCA2 may be applied in the future. This evidence concerns the gene BRCA2 and ovarian carcinoma.